Reveal Genomics and Ona link on ONA-255 development for cancer
Reveal Genomics and Ona Therapeutics have formed a strategic partnership to expedite the clinical development of the antibody-drug conjugate (ADC),…
Oncology
-
-
Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial
Patients with an advanced type of skin melanoma in England will be given expedited access to a new vaccine being…
-
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with…
-
AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a…
-
FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer
Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd),…
-
Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through…
-
EC approves extension of indication for Janssen-Cilag’s Darzalex
The European Commission (EC) has approved the extension of indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous (SC) formulation to be…
-
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC)…
-
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to…
-
NBE Therapeutics opens ADC research facility in Switzerland
Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) research and development (R&D) facility in Basel, Switzerland.…
